Jung-Woo Chae

List of Publications by Year
in descending order

62 papers	507 citations	759233 12 h-index	794594 19 g-index
63 all docs	63 docs citations	63 times ranked	875 citing authors

#	Article	IF	Citations
1	Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. Pharmaceutics, 2022, 14, 244.	4.5	4
2	A simple time-to-event model with NONMEM featuring right-censoring. Translational and Clinical Pharmacology, 2022, 30, 75.	0.9	0
3	The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics, 2022, 14, 1446.	4.5	2
4	Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. Carbohydrate Polymers, 2021, 253, 117187.	10.2	41
5	Dose Optimization of Vancomycin Using a Mechanism-based Exposure–Response Model in Pediatric Infectious Disease Patients. Clinical Therapeutics, 2021, 43, 185-194.e16.	2.5	4
6	Molecular design of anticancer drugs from marine fungi derivatives. RSC Advances, 2021, 11, 20173-20179.	3.6	9
7	Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data. Pharmaceuticals, 2021, 14, 114.	3.8	1
8	Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. Biopharmaceutics and Drug Disposition, 2021, 42, 94-102.	1.9	1
9	External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. British Journal of Clinical Pharmacology, 2021, 87, 3878-3889.	2.4	4
10	Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index. Risk Management and Healthcare Policy, 2021, Volume 14, 1855-1867.	2.5	1
11	Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case. Korean Journal of Clinical Pharmacy, 2021, 31, 125-135.	0.3	0
12	Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models. Pharmaceuticals, 2021, 14, 654.	3.8	1
13	Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients. Korean Journal of Clinical Pharmacy, 2021, 31, 237-246.	0.3	0
14	Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. Mitochondrion, 2020, 54, 65-71.	3.4	4
15	Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor–Mediated Recycling of HL2351, a Novel Hybrid Fc–Fused Interleukin–1 Receptor Antagonist, to Optimize Dosage Regimen. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 584-595.	2.5	4
16	Clinical Evaluation of Acetaminophen–Galgeuntang Interaction Based on Population Approaches. Pharmaceutics, 2020, 12, 1182.	4.5	3
17	Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics, 2020, 12, 1040.	4.5	4
18	Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans. International Journal of Molecular Sciences, 2020, 21, 1862.	4.1	2

#	Article	IF	Citations
19	Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections . Risk Management and Healthcare Policy, 2020, Volume 13, 685-695.	2.5	2
20	Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients. Pharmaceutics, 2020, 12, 336.	4.5	0
21	Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients. Pharmaceutics, 2019, 11, 259.	4.5	19
22	Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. Frontiers in Pharmacology, 2019, 10, 641.	3.5	5
23	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. Breast Cancer Research and Treatment, 2018, 168, 713-721.	2.5	20
24	Prediction of Methionine and Homocysteine levels in Zucker diabetic fatty (ZDF) rats as a T2DM animal model after consumption of a Methionine-rich diet. Nutrition and Metabolism, 2018, 15, 14.	3.0	7
25	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. Journal of Pain and Symptom Management, 2018, 55, 992-997.e2.	1.2	31
26	Chemotherapyâ€associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. Psycho-Oncology, 2018, 27, 1995-2001.	2.3	5
27	Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. Supportive Care in Cancer, 2018, 26, 3669-3670.	2.2	3
28	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. Health and Quality of Life Outcomes, 2018, 16, 20.	2.4	9
29	A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption. BMC Pharmacology & Toxicology, 2018, 19, 4.	2.4	9
30	Population Pharmacokinetic Modeling and Simulation of Afloqualone to Predict Steady-state Exposure Levels. International Journal of Pharmacology, 2018, 14, 276-284.	0.3	0
31	Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 677-687.	2.5	28
32	Development of a LCâ€"MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 123-127.	2.3	0
33	Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects. BMC Medical Research Methodology, 2017, 17, 154.	3.1	5
34	Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. BMC Cancer, 2017, 17, 867.	2.6	28
35	Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.. Journal of Clinical Oncology, 2017, 35, 10018-10018.	1.6	2
36	A web-based tool to predict chemotherapy-associated cognitive impairment during survivorship.. Journal of Clinical Oncology, 2017, 35, e21609-e21609.	1.6	1

#	Article	IF	Citations
37	Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes. Toxicological Research, 2016, 32, 207-213.	2.1	14
38	Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. PLoS ONE, 2016, 11, e0164204.	2.5	36
39	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Cancer Chemotherapy and Pharmacology, 2016, 78, 623-632.	2.3	9
40	Determination of influence of food intake after a single oral dose of mosapride in beagle dogs using nonlinear mixed effect modeling. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 590-595.	1.3	1
41	Effects of food intake on pharmacokinetics of mosapride in beagle dogs. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 497-499.	1.3	6
42	Determination of Matrine in Rat Plasma after Oral Administration of Novel Korean Herbal Medicine KIOM-MA128 and Application of PK. Journal of Analytical Methods in Chemistry, 2015, 2015, 1-6.	1.6	1
43	A novel HPLC–MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 121-126.	2.8	3
44	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis, 2015, 95, 54-59.	1.9	27
45	Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. Xenobiotica, 2014, 44, 975-987.	1.1	6
46	A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Development and Industrial Pharmacy, 2014, 40, 1325-1329.	2.0	10
47	Development of a population pharmacokinetic model to describe olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 676-683.	0.6	4
48	Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Iranian Journal of Pharmaceutical Research, 2014, 13, 365-71.	0.5	4
49	Effect of dissolved oxygen in alcoholic beverages and drinking water on alcohol elimination in humans. Alcohol, 2013, 47, 27-30.	1.7	2
50	Biopharmaceutical characterization of decursin and their derivatives for drug discovery. Drug Development and Industrial Pharmacy, 2013, 39, 1523-1530.	2.0	11
51	Quantitative determination of duloxetine and its metabolite in rat plasma by HPLC–MS/MS. Biomedical Chromatography, 2013, 27, 953-955.	1.7	12
52	Simultaneous Determination of Olanzapine and its Major Metabolite N-Desmethyl Olanzapine in Rat Plasma by HPLC-MS/MS: Application of PK in Rat. Bulletin of the Korean Chemical Society, 2013, 34, 2567-2568.	1.9	0
53	Physicochemical Characterization and Toxicity of Decursin and Their Derivatives from <i>Angelica gigas</i>. Biological and Pharmaceutical Bulletin, 2012, 35, 1084-1090.	1.4	12
54	Effect of decursinol angelate on the pharmacokinetics of theophylline and its metabolites in rats. Food and Chemical Toxicology, 2012, 50, 3666-3672.	3.6	4

#	ARTICLE	IF	CITATIONS
55	Development and validation of a sensitive LCâ€"MS/MS method for the simultaneous quantitation of theophylline and its metabolites in rat plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 44-49.	2.3	13
56	Population PK/PD analysis of metformin using the signal transduction model. British Journal of Clinical Pharmacology, 2012, 74, 815-823.	2.4	12
57	Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats. Journal of Ethnopharmacology, 2012, 144, 248-254.	4.1	10
58	Quantitative Determination of Amitriptyline and Its Metabolite in Rat Plasma by Liquid Chromatography-tandem Mass Spectrometry. Bulletin of the Korean Chemical Society, 2012, 33, 2163-2167.	1.9	7
59	Pharmacokinetic characterization of decursinol derived from <i>Angelica gigas</i> Nakai in rats. Xenobiotica, 2011, 41, 895-902.	1.1	29
60	Simultaneous determination of L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in the plasma of rodents with LC-MS/MS. Arzneimittelforschung, 2011, 61, 340-346.	0.4	8
61	Development and Validation of a Robust LC-MS/MS Method for the Simultaneous Quantification of Doxifluridine and its Two Metabolites in Beagle Dog Plasma. Bulletin of the Korean Chemical Society, 2010, 31, 2235-2241.	1.9	1
62	LC-MS/MS Assay Validation for a New Immune Modulator, JHL45, and its Major Metabolite in Plasma: Application to Pharmacokinetic Studies in Rats. Bulletin of the Korean Chemical Society, 2009, 30, 2631-2636.	1.9	5